1
Home
Companies

KalVista Pharmaceuticals

#6280

Rank

$827.44M

Marketcap

US United States

Country

KalVista Pharmaceuticals
Leadership team

Dr. Christopher M. Yea Ph.D. (Chief Devel. Officer)

Mr. Thomas Andrew Crockett M.B.A. (CEO & Director)

Mr. Benjamin L. Palleiko (Chief Bus. Officer & CFO)

Products/ Services
Biotechnology, Diabetes, Health Care
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2011
Company Registration
SEC CIK number: 0001348911
Traded as
KALV
Social Media
URL
https://www.kalvista.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
History

KalVista was founded in 2012 with the mission to discover and develop ground-breaking therapies that provide a significant improvement on existing treatments. Since then, the company has rapidly progressed towards near-term clinical development with its lead program and pipeline candidates.

Mission
Our mission is to deliver life-changing medicines to patients suffering from serious and life-threatening diseases.
Vision
Our vision is to become a global leader in developing novel and innovative drugs to treat and manage debilitating conditions with unmet medical needs.
Key Team

Ms. Rachel M. Morten (Sr. VP of Regulatory Affairs & QA)

Mr. Stephen Donnelly (Director of Fin. and Company Sec.)

Dr. Michael D. Smith Pharm.D. (Sr. VP of Devel.)

Mr. John B. McKune (VP of Fin.)

Dr. Paul K. Audhya M.B.A., M.D. (Chief Medical Officer)

Dr. Edward P. Feener Ph.D. (Chief Scientific Officer)

Jarrod Aldom (VP of Corp. Communications)

Recognition and Awards
KalVista has received numerous awards, including the 2006 Frost & Sullivan Discovery Award, the BCPA Entrepreneur of the Year, and the Tiburon Strategic Advisors Top Innovation Award.
References

https://in.investing.com/equities/carbylan-therapeutics-inc

https://finance.yahoo.com/quote/KALV/profile?p=KALV

https://www.crunchbase.com/organization/kalvista-pharmaceuticals

https://companiesmarketcap.com/

https://www.kalvista.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

KalVista Pharmaceuticals
Leadership team

Dr. Christopher M. Yea Ph.D. (Chief Devel. Officer)

Mr. Thomas Andrew Crockett M.B.A. (CEO & Director)

Mr. Benjamin L. Palleiko (Chief Bus. Officer & CFO)

Products/ Services
Biotechnology, Diabetes, Health Care
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2011
Company Registration
SEC CIK number: 0001348911
Traded as
KALV
Social Media
URL
https://www.kalvista.com